Profile data is unavailable for this security.
About the company
GlaxoSmithKline Pharmaceuticals Limited is an India-based global healthcare company. The Company is engaged in the business of manufacturing, distributing and trading in pharmaceuticals. The Company has three product areas: vaccines, specialty and general medicine. Its general medicines business has a portfolio of medicines in anti-infectives, pain, vitamins medicine, nutritional, hormones, dermatologicals, respiratory and vaccines for adults and children. The Company's general medicine brands include Augmentin, Calpol, Ceftum, Eltroxin, CCM, Neosporin, Betnovate, Tenovate, T-bact and Physiogel. The Company's vaccine brands include Shingrix Herpes Zoster Vaccine, Infanrix Hexa, Synflorix, Boostrix, Havrix, Menveo, Fluarix Tetra and Varilrix. Its specialty medicine brands include Nucala, Seretide, and Trelegy Ellipta. Trelegy Ellipta, single inhaler triple therapy (SITT) for chronic obstructive pulmonary disease (COPD) patients. The Subsidiary of the Company is Biddle Sawyer Limited.
- Revenue in INR (TTM)38.01bn
- Net income in INR10.21bn
- Incorporated1924
- Employees3.11k
- LocationGlaxoSmithKline Pharmaceuticals LtdDr Annie Besant Road, WorliMUMBAI 400030IndiaIND
- Phone+91 2 224959595
- Fax+91 2 224981526
- Websitehttps://india-pharma.gsk.com/en-in/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Astrazeneca Pharma India Ltd | 21.77bn | 2.01bn | 222.98bn | 802.00 | 110.96 | -- | 92.31 | 10.24 | 80.38 | 80.38 | 871.22 | -- | -- | -- | -- | 27,150,250.00 | -- | 11.06 | -- | 18.24 | 42.78 | 49.98 | 9.23 | 9.43 | -- | 78.86 | -- | 38.57 | 32.48 | 15.59 | -28.34 | 9.89 | -34.23 | 100.00 |
| Wockhardt Ltd | 31.51bn | 220.00m | 226.64bn | 2.30k | 1,054.18 | -- | 96.44 | 7.19 | 1.32 | 1.32 | 194.54 | -- | -- | -- | -- | 13,723,870.00 | -- | -4.37 | -- | -7.67 | 65.92 | 56.50 | 0.2539 | -11.98 | -- | 1.23 | -- | -- | 7.65 | 1.15 | 89.85 | -- | 16.19 | -- |
| Pfizer Ltd | 24.82bn | 8.54bn | 230.45bn | 1.60k | 27.00 | -- | 25.24 | 9.28 | 186.60 | 186.60 | 542.67 | -- | -- | -- | -- | 15,533,980.00 | -- | 15.22 | -- | 18.50 | 65.10 | 61.73 | 34.39 | 25.99 | -- | 83.13 | -- | 50.95 | 4.02 | 1.18 | 39.23 | 8.56 | -6.02 | 28.47 |
| Emcure Pharmaceuticals Ltd | 88.50bn | 8.70bn | 282.22bn | 6.73k | 32.43 | -- | 21.70 | 3.19 | 45.91 | 45.91 | 467.02 | -- | -- | -- | -- | 13,148,240.00 | -- | 8.47 | -- | 15.86 | 59.93 | 59.30 | 10.11 | 8.99 | -- | 30.68 | -- | 0.00 | 18.59 | 9.36 | 36.76 | 52.13 | 21.35 | -- |
| Gland Pharma Ltd | 61.13bn | 8.47bn | 293.40bn | 4.35k | 34.63 | -- | 23.32 | 4.80 | 51.42 | 51.42 | 371.01 | -- | -- | -- | -- | 14,049,110.00 | -- | 10.77 | -- | 11.98 | 65.00 | 57.00 | 13.86 | 19.59 | -- | 34.31 | -- | 14.03 | -0.8512 | 16.36 | -9.57 | -2.00 | 15.15 | -- |
| J B Chemicals and Pharmaceuticals Ltd | 41.93bn | 7.54bn | 303.69bn | 5.52k | 39.88 | -- | 32.56 | 7.24 | 47.44 | 47.44 | 263.86 | -- | -- | -- | -- | 7,600,215.00 | -- | 15.91 | -- | 19.18 | 67.95 | 62.00 | 17.98 | 16.36 | -- | 164.76 | -- | 33.55 | 12.45 | 17.16 | 19.35 | 19.53 | 10.52 | 23.03 |
| Ajanta Pharma Ltd | 52.02bn | 10.15bn | 364.82bn | 9.63k | 35.96 | -- | 30.86 | 7.01 | 81.21 | 81.21 | 416.34 | -- | -- | -- | -- | 5,402,607.00 | -- | 17.31 | -- | 21.48 | 77.65 | 73.83 | 19.50 | 19.60 | -- | 96.70 | -- | 33.78 | 10.44 | 12.43 | 12.77 | 14.50 | 5.84 | 26.43 |
| IPCA Laboratories Ltd | 71.12bn | 5.84bn | 376.85bn | 18.04k | 64.57 | -- | 27.73 | 5.30 | 23.00 | 35.86 | -- | -- | -- | -- | -- | 3,941,717.00 | -- | 9.16 | -- | 12.39 | 70.13 | 60.24 | 13.33 | 11.25 | -- | 14.07 | -- | 13.42 | 16.02 | 13.97 | 34.77 | 4.00 | 20.42 | 9.86 |
| Anthem BioSciences Ltd | 19.97bn | 4.85bn | 387.55bn | 2.06k | 80.31 | -- | 63.58 | 19.41 | 8.59 | 8.59 | 35.41 | -- | -- | -- | -- | 9,682,764.00 | -- | -- | -- | -- | 61.25 | -- | 24.27 | -- | -- | -- | -- | -- | 29.96 | -- | 22.86 | -- | -- | -- |
| GlaxoSmithKline Pharmaceuticals Ltd | 38.01bn | 10.21bn | 439.51bn | 3.11k | 43.05 | -- | 40.36 | 11.56 | 60.26 | 60.26 | 224.34 | -- | -- | -- | -- | 12,209,250.00 | -- | 15.30 | -- | 25.66 | 64.24 | 56.70 | 26.86 | 16.77 | -- | 452.52 | -- | 144.35 | 8.56 | 3.06 | 57.23 | 53.14 | -31.03 | 16.00 |
| Laurus Labs Ltd | 67.22bn | 8.43bn | 545.58bn | 6.17k | 64.74 | -- | 41.64 | 8.12 | 15.61 | 15.61 | 124.44 | -- | -- | -- | -- | 10,899,350.00 | -- | 8.88 | -- | 14.31 | 58.67 | 48.18 | 12.52 | 11.88 | -- | 7.10 | -- | 13.79 | 10.18 | 14.42 | 123.18 | 7.02 | 23.60 | -- |
| Abbott India Ltd | 68.24bn | 15.24bn | 562.26bn | 3.66k | 36.89 | -- | 35.16 | 8.24 | 717.26 | 717.26 | 3,211.47 | -- | -- | -- | -- | 18,650,260.00 | -- | 22.42 | -- | 30.42 | 46.61 | 44.59 | 22.33 | 18.83 | -- | 79.05 | -- | 73.99 | 9.58 | 9.38 | 17.75 | 18.99 | 27.31 | 34.73 |
| Glenmark Pharmaceuticals Ltd | 164.68bn | 10.65bn | 563.72bn | 13.48k | 52.95 | -- | 34.89 | 3.42 | 37.72 | 37.72 | 583.32 | -- | -- | -- | -- | 12,219,440.00 | -- | 1.33 | -- | 1.92 | 71.68 | 60.15 | 6.47 | 1.82 | -- | 16.41 | -- | 39.62 | 12.77 | 4.60 | 155.14 | 6.18 | -4.24 | 0.00 |
| Alkem Laboratories Ltd | 138.90bn | 23.61bn | 645.95bn | 18.64k | 27.36 | 4.84 | 23.16 | 4.65 | 197.47 | 197.47 | 1,161.71 | 1,116.21 | 0.7427 | 1.71 | 4.97 | 7,451,003.00 | 12.89 | 12.12 | 17.55 | 17.53 | 63.60 | 60.06 | 17.35 | 14.69 | 1.87 | 18.59 | 0.1457 | 28.96 | 2.34 | 9.21 | 20.59 | 13.95 | 13.22 | 12.47 |
Data as of Feb 16 2026. Currency figures normalised to GlaxoSmithKline Pharmaceuticals Ltd's reporting currency: Indian Rupee INR
7.06%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Life Insurance Corporation of India (Investment Portfolio)as of 31 Dec 2025 | 1.83m | 1.08% |
| SBI Funds Management Ltd.as of 31 Jan 2026 | 1.66m | 0.98% |
| Kotak Mahindra Asset Management Co. Ltd.as of 31 Jan 2026 | 1.65m | 0.98% |
| The Vanguard Group, Inc.as of 04 Feb 2026 | 1.64m | 0.97% |
| Nippon Life India Asset Management Ltd. (Invt Mgmt)as of 31 Dec 2025 | 1.53m | 0.90% |
| Aditya Birla Sun Life Amc Ltd. (Investment Management)as of 31 Jan 2026 | 869.61k | 0.51% |
| Aditya Birla Sun Life Insurance Co. Ltd.as of 30 Jan 2026 | 864.46k | 0.51% |
| BlackRock Fund Advisorsas of 06 Feb 2026 | 758.00k | 0.45% |
| Bajaj Finserv Asset Management Ltd.as of 31 Jan 2026 | 660.04k | 0.39% |
| Norges Bank Investment Managementas of 30 Jun 2025 | 479.52k | 0.28% |
More ▼
Data from 31 Dec 2025 - 10 Feb 2026Source: FactSet Research Systems Inc.
